NASDAQ:PROG - Progenity Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.80
  • Forecasted Upside: 79.16 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.47
▼ -0.1 (-1.80%)
1 month | 3 months | 12 months
Get New Progenity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PROG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PROG

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.80
▲ +79.16% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Progenity in the last 3 months. The average price target is $9.80, with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 79.16% upside from the last price of $5.47.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Progenity.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
2/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2021Wells Fargo & CompanyDowngradeOverweight ➝ Underweight$5.00High
i
1/14/2021Piper SandlerLower Price TargetOverweight$15.00 ➝ $10.00High
i
11/10/2020Raymond JamesLower Price TargetOutperform$15.00 ➝ $10.00High
i
Rating by Andrew Cooper at Raymond James
11/10/2020Piper SandlerLower Price TargetAverage ➝ Overweight$17.00 ➝ $15.00High
i
Rating by Steven Mah at Piper Sandler
10/23/2020BTIG ResearchInitiated CoverageBuy$12.00Low
i
8/19/2020Raymond JamesReiterated RatingBuyHigh
i
Rating by Andrew Cooper at Raymond James
7/14/2020Piper SandlerInitiated CoverageOverweight$17.00High
i
7/14/2020Robert W. BairdInitiated CoverageOutperform$12.00Medium
i
7/14/2020Raymond JamesInitiated CoverageOutperform$15.00High
i
7/14/2020Wells Fargo & CompanyInitiated CoverageOverweight$11.00High
i
(Data available from 3/1/2016 forward)
Progenity logo
Progenity, Inc., a biotechnology company, provides complex molecular and specialized testing services to physicians, clinicians, and their patients in the United States. It offers testing services for common hereditary disorders, cystic fibrosis, spinal muscular atrophy, fragile X syndrome, and Jewish genetic diseases; pan-ethnic carrier screening services; non-invasive prenatal, miscarriage, and pharmacogenetic testing services; and ovarian assessment reports for women. The company also provides pediatric testing services. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November, 2013. The company was incorporated in 2012 and is based in San Diego, California with a laboratory in Ann Arbor, Michigan. It has a bill payment location in Detroit, Michigan.
Read More

Today's Range

Now: $5.47
$5.40
$5.61

50 Day Range

MA: $6.08
$5.34
$7.31

52 Week Range

Now: $5.47
$3.08
$15.92

Volume

319,800 shs

Average Volume

613,692 shs

Market Capitalization

$298.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Progenity?

The following Wall Street sell-side analysts have issued reports on Progenity in the last year: BTIG Research, Piper Sandler, Raymond James, Robert W. Baird, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for PROG.

What is the current price target for Progenity?

5 Wall Street analysts have set twelve-month price targets for Progenity in the last year. Their average twelve-month price target is $9.80, suggesting a possible upside of 79.2%. Robert W. Baird has the highest price target set, predicting PROG will reach $12.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $5.00 for Progenity in the next year.
View the latest price targets for PROG.

What is the current consensus analyst rating for Progenity?

Progenity currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PROG will outperform the market and that investors should add to their positions of Progenity.
View the latest ratings for PROG.

What other companies compete with Progenity?

How do I contact Progenity's investor relations team?

Progenity's physical mailing address is 4330 LA JOLLA VILLAGE DRIVE SUITE 200, SAN DIEGO CA, 92122. The company's listed phone number is 855-293-2639 and its investor relations email address is [email protected] The official website for Progenity is www.progenity.com.